Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lessened its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 91.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 73,823 shares of the company's stock after selling 788,067 shares during the quarter. Victory Capital Management Inc.'s holdings in Roivant Sciences were worth $829,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Roivant Sciences by 8.1% during the 3rd quarter. FMR LLC now owns 38,910,625 shares of the company's stock valued at $454,476,000 after acquiring an additional 2,913,491 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Roivant Sciences by 48.7% during the 3rd quarter. Morgan Stanley now owns 19,311,631 shares of the company's stock valued at $225,560,000 after acquiring an additional 6,324,915 shares in the last quarter. Rubric Capital Management LP boosted its holdings in shares of Roivant Sciences by 196.9% during the 3rd quarter. Rubric Capital Management LP now owns 10,500,000 shares of the company's stock valued at $122,640,000 after acquiring an additional 6,963,562 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Roivant Sciences by 159.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,602,566 shares of the company's stock valued at $65,438,000 after acquiring an additional 3,440,374 shares in the last quarter. Finally, Loomis Sayles & Co. L P lifted its holdings in Roivant Sciences by 1.2% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,984,935 shares of the company's stock worth $23,184,000 after buying an additional 24,428 shares during the period. Institutional investors and hedge funds own 64.76% of the company's stock.

Analyst Upgrades and Downgrades

ROIV has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a report on Monday, April 22nd. Deutsche Bank Aktiengesellschaft lifted their target price on Roivant Sciences from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. Wolfe Research initiated coverage on Roivant Sciences in a report on Thursday, February 15th. They set an "outperform" rating and a $17.00 target price on the stock. Truist Financial reaffirmed a "buy" rating and set a $23.00 target price on shares of Roivant Sciences in a report on Monday, March 25th. Finally, TheStreet raised Roivant Sciences from a "d" rating to a "c+" rating in a report on Tuesday, February 13th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.90.

Roivant Sciences Trading Up 0.5 %

Shares of ROIV stock traded up $0.06 during mid-day trading on Wednesday, hitting $11.29. The company's stock had a trading volume of 4,723,481 shares, compared to its average volume of 6,179,250. Roivant Sciences Ltd. has a 52 week low of $8.24 and a 52 week high of $13.24. The company has a market cap of $9.10 billion, a PE ratio of 2.19 and a beta of 1.30. The company's fifty day simple moving average is $10.89 and its 200-day simple moving average is $10.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.